会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 56. 发明申请
    • MODULATION OF INFLAMMATION BY PROTEASE-TREATED MCP-3 CHEMOKINE
    • 通过蛋白酶处理的MCP-3 CHEMOKINE进行调节
    • WO0190361A3
    • 2002-08-08
    • PCT/CA0100741
    • 2001-05-25
    • UNIV BRITISH COLUMBIAOVERALL CHRISTOPHER MARKMCQUIBBAN G ANGUSCLARK-LEWIS IAN
    • MCQUIBBAN G ANGUSCLARK-LEWIS IAN
    • A61K38/00A61P29/00A61P35/00A61P37/06C07K14/52C12N15/19A61K38/19
    • C07K14/523A61K38/00
    • The invention provides methods of inhibiting the biological activity or the in vivo biological activity of CC-chemokines (including native MCP-3), such as methods of inhibiting inflammation, comprising administering to a host an effective amount of a CC-chemokine receptor antagonist of the present invention. In some embodiments, the invention may provide methods of modulating an immune response in a host, or treating inflammation or autoimmune disease in a host suffering from such diseases, comprising administering to the host an effective amount of a CC-chemokine receptor antagonist of the present invention. Another aspect of the present invention is directed to pharmaceutical compositions comprising an antagonistically effective amount of a CC-chemokine receptor antagonist of the present invention and a pharmaceutically acceptable carrier. In alternative aspects, the invention provides compounds and methods for cancer treatment that facilitate an effective immune response.
    • 本发明提供抑制CC趋化因子(包括天然MCP-3)的生物学活性或体内生物学活性的方法,例如抑制炎症的方法,包括向宿主施用有效量的CC-趋化因子受体拮抗剂 本发明。 在一些实施方案中,本发明可以提供调节宿主中的免疫应答或在患有这些疾病的宿主中治疗炎症或自身免疫性疾病的方法,包括向宿主施用有效量的本发明的CC-趋化因子受体拮抗剂 发明。 本发明的另一方面涉及包含拮抗有效量的本发明的CC-趋化因子受体拮抗剂和药学上可接受的载体的药物组合物。 在替代方面,本发明提供了促进有效免疫应答的用于癌症治疗的化合物和方法。